MDWD (MediWound) Float Percentage Of Total Shares Outstanding: 87.51% (As of Jul. 06, 2026)


MDWD MediWound Ltd MDWD
56 GF Score
Price $15.16
GF Value $12.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound Float Percentage Of Total Shares Outstanding?

MediWound MDWD +2.19% 56 Float Percentage Of Total Shares Outstanding is 87.51% as of Jul. 06, 2026. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MediWound's float shares is 11.24 Mil. MediWound's total shares outstanding is 12.85 Mil. MediWound's float percentage of total shares outstanding is 87.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MediWound's Insider Ownership is 0.10%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MediWound's Institutional Ownership is 50.13%.

MDWD
56GF Score
MediWound Ltd MDWD
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediWound Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MediWound's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=11.24/12.85
=87.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 87.51% mean?
MediWound (MDWD) has a Float Percentage Of Total Shares Outstanding of 87.51% as of Jul. 06, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MediWound and its competitors.
Is MediWound's Float Percentage Of Total Shares Outstanding too high?
MediWound's current Float Percentage Of Total Shares Outstanding is 87.51%. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Float Percentage Of Total Shares Outstanding compare to UNCY and ARCT?
MediWound's Float Percentage Of Total Shares Outstanding of 87.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MediWound and its competitors. MediWound's current Float Percentage Of Total Shares Outstanding is 87.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 87.51%. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For MediWound (MDWD), the current Float Percentage Of Total Shares Outstanding is 87.51% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

  • Float Percentage Of Total Shares Outstanding: 87.51%
  • GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Other Exchanges M8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score

Get the complete analysis for MDWD

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.16
Price
$12.44
GF Value